Zhejiang Medicine Co Ltd (Zhejiang Medicine) discovers, develops, and markets drugs and finished formulations. The company offers Citronellal, Citronellol, Geraniol 600, Geraniol 980, Linalyl acetate, Tetrahydrolinalool, Linalool, Ionone Beta, Citral, Vitamin A, E, and combination soft capsules, Testosterone Undecanoate and Progesterone soft capsules, Omeprazole and Rifampicin capsules, Vancomycin Hydrochloride for injection, and active pharmaceutical ingredients including Daptomycin, Vancomycin Hydrochloride, Teicoplanin, Minocycline Hydrochloride, Levofloxacin, Linezolid, and Rifamycin O. Zhejiang Medicine classifies its product portfolio into seven categories, namely Vitamins and Vitamin Derivatives Series, Anti-infective Medicines, Hypoglycemic (Blood Sugar Lowering) Medicines, Hormone Medicines, Nutritional Supplement Products, Pharmaceutical Commercial Distribution, and Others.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Zhejiang Medicine is currently a producer of domestic anti-drug resistant antibiotics and fluoroquinolone antibiotics. The company has a strong focus on R&D, production, and market development, with significant international competitiveness. It emphasizes original research and technological innovation with independent intellectual property rights. The company has established two technical platforms for industrial green chemistry and microencapsulation of active ingredients in the field of vitamin products. The R&D units of the company include the Shaoxing Pharmaceutical Industry Research Institute and the Shanghai Laiyi Biological Drug Research and Development Center. The Shaoxing Pharmaceutical Industry Research Institute comprises seven professional research institutes with nearly 200 scientific researchers focused on new drugs, new product research and development, and process and equipment technology innovation. The Shanghai Laiyi Biological Drug Research and Development Center, co-constructed with China Pharmaceutical University and Shanghai Jiaotong University, focuses on new drug screening, activity research, new technology development, generic drug development, process optimization, and export certification technical support. The company has two R&D centers. It holds 563 domestic invention patents and 164 international invention patents. In FY2025, the company spent CNY579.8 million on its research and development activities which as a percentage of revenue stood at 6.5%.